Zoetis Receives EU Approval for New Vaccine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Zoetis announced that the European Commission, or EC, has granted marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease, or ND, and Marek's disease viruses. The vaccine provides protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU animal health regulations and a significant cause of mortality and production losses in commercial poultry. Two other vaccines have received European Commission marketing authorization. Poulvac Procerta HVT-IBD, the first in the range to receive this authorization, protects against infectious bursal disease and Marek's disease. Poulvac Procerta HVT-IBD-ND, authorized in 2025, protects against Newcastle disease, infectious bursal disease, and Marek's disease in a single dose.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 75.420
Low
130.00
Averages
154.20
High
200.00
Current: 75.420
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 27, 2026.
- Disappointing Earnings Report: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, down from the previous range of $7.00 to $7.10.
- Significant Market Reaction: Following the earnings release, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, indicating investor concerns regarding the company's future profitability.
- Challenging Operating Environment: CEO Kristin Peck noted that the first quarter unfolded in a more challenging operating environment than anticipated, with increased price sensitivity among pet owners leading to a decline in veterinary visits and softer demand, adversely affecting the company's performance.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Zoetis Inc., covering investors who purchased securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Market Reaction: On May 7, 2026, Zoetis reported a significant decline in its Companion Animal business in its first-quarter financial results, leading to a 21.5% drop in stock price, reflecting market concerns and a loss of confidence in the company's future prospects.
- Competitive Pressure: The lawsuit highlights that Zoetis's products, including Librela and Simparica Trio, are facing competitive pressures, particularly with Simparica Trio losing significant market share, which adversely affects the company's overall performance.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the class action lawsuit, ensuring their rights to any potential recovery from the litigation.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: AeroVironment is facing allegations for failing to disclose competitive risks related to the U.S. Space Force from June 2025 to March 2026, which misled investors about its business prospects and could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix is accused of not informing investors about supply chain issues that affected its first-quarter margins due to advanced purchasing of memory components, leading to distorted market expectations regarding its profitability and potential shareholder claims.
- Zoetis Lawsuit: Zoetis failed to disclose a decline in market share for its veterinary prescription drugs, particularly Librela and Simparica Trio, from January 2025 to May 2026, which may weaken investor confidence in the company's future growth.
- Lucid Group Lawsuit: Lucid Group's product deliveries were significantly disrupted by supplier quality issues in early 2026, and the company did not disclose this to investors, potentially leading to substantial negative impacts on its financial results and affecting shareholder investment decisions.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, to file a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, down from $7.00 to $7.10, indicating a more challenging operating environment than anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting strong investor concerns regarding the company's outlook.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations for investors seeking to recover losses due to corporate wrongdoing, with its founding partner having recovered over $5.5 billion for aggrieved investors, showcasing its expertise in such cases.
See More
Zoetis Faces Shareholder Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to these misrepresentations, investors suffered significant losses when the truth was revealed, indicating serious issues regarding the company's business operations and financial stability, which could undermine future investor confidence.
- Participation Requirements: Investors are encouraged to act promptly and submit a form to join the lawsuit, and those wishing to serve as lead plaintiffs must file papers by July 27, 2026, demonstrating an active interest in the litigation process.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which may attract more investors to participate in the lawsuit and increase legal pressure on the company.
See More
Analyst Target Price vs ETF Performance Analysis
- ETF Potential Analysis: The iShares US Pharmaceuticals ETF (IHE) has an implied analyst target price of $109.89 per unit, while trading at $100.19, indicating a 9.68% upside, reflecting market optimism about the ETF's future performance.
- Outstanding Stock Performance: Crinetics Pharmaceuticals (CRNX) trades at $42.03, with an analyst target price of $83.14, suggesting a potential upside of 97.82%, showcasing strong market confidence in its future growth.
- Optimistic Industry Outlook: CorMedix (CRMD) is priced at $8.79, with a target price of $14.00, indicating a 59.27% upside, reflecting analysts' positive expectations regarding its products and market demand.
- Zoetis Growth Potential: Zoetis (ZTS) trades at $75.42, with an analyst target price of $114.12, showing a 51.32% upside, indicating analysts' optimism about its continued growth in the animal health sector.
See More
Zoetis Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 27, 2026.
- Disappointing Earnings Report: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, down from the previous range of $7.00 to $7.10.
- Significant Market Reaction: Following the earnings release, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, indicating investor concerns regarding the company's future profitability.
- Challenging Operating Environment: CEO Kristin Peck noted that the first quarter unfolded in a more challenging operating environment than anticipated, with increased price sensitivity among pet owners leading to a decline in veterinary visits and softer demand, adversely affecting the company's performance.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Zoetis Inc., covering investors who purchased securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Market Reaction: On May 7, 2026, Zoetis reported a significant decline in its Companion Animal business in its first-quarter financial results, leading to a 21.5% drop in stock price, reflecting market concerns and a loss of confidence in the company's future prospects.
- Competitive Pressure: The lawsuit highlights that Zoetis's products, including Librela and Simparica Trio, are facing competitive pressures, particularly with Simparica Trio losing significant market share, which adversely affects the company's overall performance.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the class action lawsuit, ensuring their rights to any potential recovery from the litigation.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: AeroVironment is facing allegations for failing to disclose competitive risks related to the U.S. Space Force from June 2025 to March 2026, which misled investors about its business prospects and could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix is accused of not informing investors about supply chain issues that affected its first-quarter margins due to advanced purchasing of memory components, leading to distorted market expectations regarding its profitability and potential shareholder claims.
- Zoetis Lawsuit: Zoetis failed to disclose a decline in market share for its veterinary prescription drugs, particularly Librela and Simparica Trio, from January 2025 to May 2026, which may weaken investor confidence in the company's future growth.
- Lucid Group Lawsuit: Lucid Group's product deliveries were significantly disrupted by supplier quality issues in early 2026, and the company did not disclose this to investors, potentially leading to substantial negative impacts on its financial results and affecting shareholder investment decisions.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, to file a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, down from $7.00 to $7.10, indicating a more challenging operating environment than anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting strong investor concerns regarding the company's outlook.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations for investors seeking to recover losses due to corporate wrongdoing, with its founding partner having recovered over $5.5 billion for aggrieved investors, showcasing its expertise in such cases.
See More
Zoetis Faces Shareholder Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to these misrepresentations, investors suffered significant losses when the truth was revealed, indicating serious issues regarding the company's business operations and financial stability, which could undermine future investor confidence.
- Participation Requirements: Investors are encouraged to act promptly and submit a form to join the lawsuit, and those wishing to serve as lead plaintiffs must file papers by July 27, 2026, demonstrating an active interest in the litigation process.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which may attract more investors to participate in the lawsuit and increase legal pressure on the company.
See More
Analyst Target Price vs ETF Performance Analysis
- ETF Potential Analysis: The iShares US Pharmaceuticals ETF (IHE) has an implied analyst target price of $109.89 per unit, while trading at $100.19, indicating a 9.68% upside, reflecting market optimism about the ETF's future performance.
- Outstanding Stock Performance: Crinetics Pharmaceuticals (CRNX) trades at $42.03, with an analyst target price of $83.14, suggesting a potential upside of 97.82%, showcasing strong market confidence in its future growth.
- Optimistic Industry Outlook: CorMedix (CRMD) is priced at $8.79, with a target price of $14.00, indicating a 59.27% upside, reflecting analysts' positive expectations regarding its products and market demand.
- Zoetis Growth Potential: Zoetis (ZTS) trades at $75.42, with an analyst target price of $114.12, showing a 51.32% upside, indicating analysts' optimism about its continued growth in the animal health sector.
See More
